Ghazisaeedi F, Meens J, Hansche B, Maurischat S, Schwerk P, Goethe R, Wieler LH, Fulde M, Tedin K. A
Gut Microbes. 2022 Jan-Dec;14(1):2106105.
doi: 10.1080/19490976.2022.2106105

Beneficial microbes confer health benefits to the host and have been used as both prophylactics and therapeutics in human and animal over last decades. The authorized probiotic strain Enterococcus faecium SF68 (NCIMB 10415) is an endogenous lactic acid bacteria (LAB) strain with mainly anti-inflammatory effects and has been shown to mitigate symptoms of human and animal intestinal inflammation. In previous animal trials with weaning piglets performed in our laboratory or in cooperation with our laboratory, we observed reduced expression of immune-associated genes in intestinal tissues and associated lymphoid organs.

In our newest publication we showed that E. faecium SF68 has reversible NF-κB inhibitory effects in intestinal epithelial cells and the arginine deiminase of the AD pathway in E. faecium SF68 is most likely responsible for the observed in vitro and in vivo immunomodulatory effects of this probiotic strain.

Previous in vivo observations on E. faecium SF68 and involvement of arginine deiminase, a potential bacterial virulence factor, in the anti-inflammatory effects of this probiotic strain underline the importance of individual and cautious assessments and decisions on the administration of a beneficial microbe for therapeutic or preventive purposes in human and animal health.